Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIRE 2 bococizumab cardiovascular outcomes trial
NL-OMON44656Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jun 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of bococizumab in dyslipidemia, cardiac morbidity, sponsored by Pfizer. Started Jun 2014; status: active, not recruiting.
02
Drugs
bococizumab
03
Conditions
dyslipidemiacardiac morbidity
Beyond the preview
Go deeper on NL-OMON44656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44656.